TY - JOUR
T1 - Ceftobiprole for the treatment of infective endocarditis
T2 - A case series
AU - Tascini, Carlo
AU - Attanasio, Vittorio
AU - Ripa, Marco
AU - Carozza, Antonio
AU - Pallotto, Carlo
AU - Bernardo, Mariano
AU - Francisci, Daniela
AU - Oltolini, Chiara
AU - Palmiero, Giulia
AU - Scarpellini, Paolo
N1 - Publisher Copyright:
© 2019 International Society for Antimicrobial Chemotherapy
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/3
Y1 - 2020/3
N2 - Objectives: Ceftobiprole is a relatively new cephalosporin with broad-spectrum activity and good tolerability. Despite its promising characteristics, to our knowledge, only two case reports, previously published also by some of us, is available concerning its administration for the treatment of infective endocarditis. Hereby we report our experience in this field. Methods: All the patients with infective endocarditis treated with ceftobiprole were enrolled. Results: 12 cases of endocarditis were treated with ceftobiprole, 11/12 in combination with daptomycin and 1/12 as monotherapy. Gram-positive bacteria were isolated in 12/12 patients; 3 cases were polymicrobial. Cure rate was 83% (10/12 patients). In 9/12 (75%) cases, patients were switched to ceftobiprole following failure of previous antimicrobial regimen. In 3/3 patients in which ceftobiprole was administered because of persistently positive blood culture, bacteraemia clearance was rapidly achieved. Conclusions: Ceftobiprole, especially in combination, could be a promising alternative treatment for infective endocarditis.
AB - Objectives: Ceftobiprole is a relatively new cephalosporin with broad-spectrum activity and good tolerability. Despite its promising characteristics, to our knowledge, only two case reports, previously published also by some of us, is available concerning its administration for the treatment of infective endocarditis. Hereby we report our experience in this field. Methods: All the patients with infective endocarditis treated with ceftobiprole were enrolled. Results: 12 cases of endocarditis were treated with ceftobiprole, 11/12 in combination with daptomycin and 1/12 as monotherapy. Gram-positive bacteria were isolated in 12/12 patients; 3 cases were polymicrobial. Cure rate was 83% (10/12 patients). In 9/12 (75%) cases, patients were switched to ceftobiprole following failure of previous antimicrobial regimen. In 3/3 patients in which ceftobiprole was administered because of persistently positive blood culture, bacteraemia clearance was rapidly achieved. Conclusions: Ceftobiprole, especially in combination, could be a promising alternative treatment for infective endocarditis.
KW - Ceftobiprole
KW - Infective endocarditis
KW - MRSA
UR - http://www.scopus.com/inward/record.url?scp=85073635699&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073635699&partnerID=8YFLogxK
U2 - 10.1016/j.jgar.2019.07.020
DO - 10.1016/j.jgar.2019.07.020
M3 - Article
C2 - 31351247
AN - SCOPUS:85073635699
VL - 20
SP - 56
EP - 59
JO - Journal of Global Antimicrobial Resistance
JF - Journal of Global Antimicrobial Resistance
SN - 2213-7165
ER -